Stock Market & Financial Investment News

News Breaks November 4, 2012 12:25 EDT AMGN Amgen: Phase 3 EVOLVE trial results presented Amgen announced results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar®/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular, CV, events among 3,883 patients with secondary hyperparathyroidism, HPT, and chronic kidney disease, CKD, receiving dialysis. The primary endpoint of the study was time to the composite event comprising all-cause mortality or first non-fatal CV event, including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event. Although patients in the Sensipar/Mimpara arm experienced a seven percent reduction in the primary endpoint (Hazard Ratio 0.93, 95 percent CI 0.85 to 1.02, p=0.112), the results were not statistically significant, and the trial did not meet its primary endpoint in the intent-to-treat analysis. These data were published today in the New England Journal of Medicine and simultaneously presented at the American Society of Nephrology's Kidney Week. News For AMGN From The Last 14 Days Check below for free stories on AMGN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 19:07 EDT AMGN On The Fly: After Hours Movers Subscribe for More Information 17:25 EDT AMGN Amgen reports 7.58% stake in Cytokinetics Subscribe for More Information June 16, 2013 11:44 EDT AMGN Amgen still looks attractive, Barron's says Subscribe for More Information June 13, 2013 11:06 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 11:04 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 07:32 EDT AMGN European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 09:13 EDT AMGN Amgen, AstraZeneca to advance brodalumab into Phase 3 studies Subscribe for More Information 09:04 EDT AMGN Amgen announces positive top-line results of Phase 3 trebananib Subscribe for More Information 07:39 EDT AMGN Amgen, Cytokinetics announce expansion of license for omecamtiv mecarbil Subscribe for More Information June 11, 2013 07:31 EDT AMGN Goldman to host a conference Subscribe for More Information June 10, 2013 07:40 EDT AMGN Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT AMGN Biomed to host a conference Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.